ASCORBIC ACID Drug Patent Profile
When do Ascorbic Acid patents expire, and when can generic versions of Ascorbic Acid launch?
Ascorbic Acid is a drug marketed by Fresenius Kabi Usa, Pharmobedient, and Zydus Pharms. and is included in three NDAs.
The generic ingredient in ASCORBIC ACID is ascorbic acid. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the ascorbic acid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ascorbic Acid
A generic version of ASCORBIC ACID was approved as ascorbic acid by FRESENIUS KABI USA on August 7th, 2025.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ASCORBIC ACID?
- What are the global sales for ASCORBIC ACID?
- What is Average Wholesale Price for ASCORBIC ACID?
Summary for ASCORBIC ACID
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 152 |
| Clinical Trials: | 230 |
| Drug Prices: | Drug price information for ASCORBIC ACID |
| DailyMed Link: | ASCORBIC ACID at DailyMed |
Recent Clinical Trials for ASCORBIC ACID
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Baylor College of Medicine | EARLY_PHASE1 |
| The Methodist Hospital Research Institute | EARLY_PHASE1 |
| Center for Cell and Gene Therapy, Baylor College of Medicine | EARLY_PHASE1 |
Pharmacology for ASCORBIC ACID
| Drug Class | Vitamin C |
Medical Subject Heading (MeSH) Categories for ASCORBIC ACID
Anatomical Therapeutic Chemical (ATC) Classes for ASCORBIC ACID
US Patents and Regulatory Information for ASCORBIC ACID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 217131-001 | Aug 7, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Pharms | ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 220873-002 | Aug 20, 2026 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmobedient | ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 220172-001 | Jul 30, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Pharms | ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 220873-001 | Aug 20, 2026 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zydus Pharms | ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 220873-003 | Aug 20, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
